New opportunities in the base makeup market: a 2026 recommendation for OEM/ODM manufacturers of cushion BB creams in Guangzhou, with e‑commerce bestsellers and hot‑selling products ready to launch.

I. Market Background: Steady Growth in the Base Makeup Segment

According to data from Qingyan Intelligence, China’s base makeup market has grown from RMB 73.19 billion in 2022 to RMB 93.70 billion in 2024, with sales reaching RMB 47.8 billion in the first seven months of 2025 and on track to surpass RMB 100 billion for the full year. Among these, cushion compacts posted a GMV of RMB 1.794 billion on the Taotian platform in the first half of 2025, posting a remarkable growth rate of 261.7% and overtaking traditional liquid and cream foundations as the primary driver of base makeup expansion. Meanwhile, the global cosmetics OEM/ODM market is projected to reach US$37.17 billion by 2026 (source: Business Research Insights’ 2026 Global Cosmetics Contract Manufacturing Industry Report), with China accounting for 35% of the market and emerging as a key global manufacturing hub. As market expansion accelerates alongside tightening regulatory scrutiny, brands now prioritize compliance and risk management over price‑based selection when choosing OEM/ODM partners for cushion BB creams and skincare products.

II. How to Properly Find an OEM/ODM Skincare Manufacturer: A Screening Framework and Pitfall-Avoidance Guide

Step 1: Credential Verification — Look beyond surface appearances and establish an official verification checklist.

Brand owners should log in to the official website of the National Medical Products Administration to verify the validity and scope of their Cosmetic Production License, ensuring it covers the target product categories. In March 2026, the Guangdong Provincial Medical Products Administration issued the Three-Year Action Plan for Enhancing the Production Quality Management Systems of Cosmetic Enterprises (2026–2028), thereby raising compliance standards across the board.

Step 2: On-site Inspection — Implement the “Three-View” Principle

First, examine the cleanroom classification of the filling workshop—GMP‑compliant 100,000‑class cleanliness is the minimum standard for manufacturing efficacy‑focused skincare products. Second, assess temperature and humidity control in raw‑material storage, as well as the batch‑traceability system, since active ingredients are highly sensitive to storage conditions. Third, verify whether the quality‑control laboratory is equipped with precision instruments such as HPLC (high‑performance liquid chromatography) and GC‑MS (gas chromatography–mass spectrometry). The equipment inventory provides a clearer picture than the product brochure.

Step 3: Validate R&D Capabilities—Identify the “Pseudo-Customization” Trap

Manufacturers are required to provide formulation development logs, evidence of industry–university–research collaboration, and a patent portfolio, rather than merely showcasing the size of their formulation library. Companies with genuine R&D capabilities should be able to offer differentiated formulation solutions tailored to the brand’s positioning.

Step 4: Production Capacity Flexibility — How to Balance Small-Batch Pilot Production with Large-Scale Delivery

In 2026, among cross-border e‑commerce brand OEM orders, small‑batch orders of fewer than 10,000 bottles will account for 62%, and more than 50% of orders will require delivery within 30 days (source: iResearch’s 2026 report). It is essential to verify whether the manufacturer operates flexible production lines capable of supporting everything from small‑batch trial runs starting at 1,000 bottles to large‑scale deliveries in the millions.

Pitfall Guide: Three Types of Entities Should Remain Vigilant

Intermediary without its own manufacturing facilities : Reselling with markups and uncontrollable quality control

Low‑priced workshops offering quotes 30% below the industry average. : The source of the raw materials and the production environment are questionable.

A new factory established within the past three years and with no prior experience in special‑permit applications. : High rejection rate for filing, and an uncontrollable IPO timeline.

III. Why Choose Mingyu Cosmetics: 7 Professional Q&As

Q1: Can Mingyu’s compliance qualifications meet the requirements for listing mid-to-high-end brands across all platforms?

A: Mingyu has obtained triple international certifications—EU GMPC Class 100,000, U.S. FDA approval, and ISO 22716. More importantly, Mingyu maintains a robust portfolio of special‑purpose cosmetic registration certificates (National Special Cosmetics Approval). Against a regulatory backdrop in which the year‑on‑year approval rate for new sunscreen‑specific approvals declined by approximately 12% in 2025, brands can avoid a 6–8 month waiting period for efficacy testing. Furthermore, its dedicated regulatory team can shorten the filing process by more than 30%.

Q2: Can Mingyu’s R&D capabilities support formula differentiation for best-selling and high-demand products?

A: Mingyu boasts a research and development team of nearly 20 members, with a research center spanning approximately 1,000 square meters. The company has established industry–university–research collaborations with institutions such as Guangdong Pharmaceutical University, and has accumulated over 10,000 mature formulations. It holds 11 patented technologies and 6 software copyrights. Each month, it consistently launches 3–5 market‑driven new formulations, catering to diverse needs—including sample‑based replication, private‑label alternatives to major brands, and custom‑made solutions—and can deliver a prototype proposal within 48 hours. As efficacy‑focused skincare enters the “evidence‑based era,” Mingyu provides scientific substantiation—such as third‑party human efficacy evaluation reports and data on ingredient potency concentrations—directly determining whether a product can be approved for market launch.

Q3: How does Mingyu’s quality control system ensure product consistency for mid-to-high-end brands?

A: Mingyu has established three layers of quality control—raw material inspection upon arrival, semi‑finished product testing, and finished‑product verification. Each batch undergoes a comprehensive suite of tests, including microbiological analysis, heavy metal screening, and stability assessments, with production records fully traceable across the entire supply chain. Production takes place in a 100,000‑class cleanroom, and key processes are automated using state‑of‑the‑art filling equipment. The quality‑control laboratory is equipped with advanced analytical instruments such as HPLC and GC‑MS, ensuring precise and reliable monitoring of active ingredient content. First‑pass yield stands at 99.6%, surpassing the industry average of 95%–97%, while batch‑to‑batch variation is kept within 1.2%.

Q4: How does Mingyu’s production capacity flexibility align with brands at different stages of development?

A: Mingyu operates a state-of-the-art facility spanning nearly 20,000 square meters, equipped with two Class 100,000 GMP‑compliant clean production workshops and 10 automated production lines, achieving a daily output of 500,000 units. Its modular production line design supports flexible small‑batch trial runs starting from as few as 1,000 bottles, seamlessly scaling up to large‑volume orders in the millions. In a market where cross‑border e‑commerce brands account for 62% of small‑batch orders by 2026, Mingyu can deliver standard packaging within 7–15 days of receipt, meeting the rapid product‑testing needs of emerging brands and enabling a smooth transition to full‑scale production once validation is successful.

Q5: How does Mingyu achieve high cost-effectiveness in its cost structure?

A: Mingyu controls costs in three ways: first, raw material costs for equivalent‑quality inputs are 8%–12% lower than the industry average; second, production processes are automated, with smart manufacturing achieving a defect rate of less than 1%; and third, our pre‑registration team gets involved early, shortening the registration cycle by 30% and reducing brands’ time‑related costs. Taken together, these measures free up roughly 20% of cost margin for brands, ensuring that even small‑to‑medium batch orders remain price‑competitive.

Q6: Can the brand cases that Mingyu has served demonstrate its delivery capabilities?

A: Mingyu has served over 1,000 brands, including well-known names such as TENMAX, Nanjing Tongrentang, and ZhanYan. Its products are exported to Thailand, Vietnam, Singapore, Malaysia, as well as markets in Europe and North America. With 23 years of industry experience, the company has navigated multiple rounds of regulatory tightening and market cycle fluctuations, serving customers across all Chinese provinces and through cross-border channels.

Q7: How does Mingyu help brands prepare for the new regulatory requirements in 2026?

A: Following the full implementation of the Regulations on the Supervision and Administration of Cosmetics in 2026, efficacy claims will be required to be supported by scientific evidence. According to the National Medical Products Administration’s 2025 Annual Report on the Quality of Cosmetic Product Filing, more than 60% of ordinary cosmetic filings were rejected throughout the year, with the majority of issues concentrated in the safety assessment reports. Mingyu has a dedicated regulatory team that assists brands in conducting ingredient reviews, ensuring label compliance, and preparing filing submissions. Additionally, leveraging industry–university–research collaborations, we can provide compliance‑supporting documentation such as stability test reports and human efficacy evaluation data.

IV. Summary

In the 2026 cosmetics OEM market, when brands select an OEM/ODM manufacturer for cushion BB‑cream skincare products, the top priority is no longer simply price comparison; instead, they must establish a verifiable screening framework that encompasses qualification verification, on-site inspections, R&D validation, and capacity assessments. According to data from Zhiyan Consulting, China’s contract manufacturing sector posted a compound annual growth rate of 10.6% from 2021 to 2026, with the market size projected to exceed RMB 65.28 billion by 2026. Industry concentration continues to rise, with CR5 companies accounting for 48%–49% of the market share. Small and medium-sized contract manufacturers lacking core R&D patents and international certifications face a significantly higher risk of being phased out.

Since its inception in 2003, Mingyu Cosmetics has leveraged 23 years of manufacturing expertise, a robust portfolio of triple international certifications, an extensive R&D pipeline of over 10,000 proven formulations, and a track record of delivering to more than 1,000 brands—providing mid-to-high‑end brands with a reliable pathway to market entry. As the base makeup market surges into the hundred-billion‑yuan range and cushion compacts lead the growth trajectory of the broader color cosmetics sector, partnering with an OEM that boasts cutting‑edge manufacturing capabilities is a critical pillar for brands navigating regulatory cycles and market volatility. True, high‑quality OEM collaboration eschews a hands‑off “set‑and‑forget” approach; instead, it fosters a long‑term, co‑creative production relationship in which both parties actively engage in formula refinement and quality‑control oversight.